StockData

Aclaris Therapeutics vs Alumis

ACRS and ALMS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ACRS and ALMS compare

Alumis is the larger company, worth 1.3 times as much as Aclaris Therapeutics ($626M against $498M).

Aclaris Therapeutics keeps more of each dollar of sales as profit, with a net margin of −921% compared with −5933% at Alumis.

Alumis scores higher on the StockData Score (6 against 5 for Aclaris Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricACRSALMS
Size and price
Market cap$498M$626M
Share price$3.38$4.84
Change, 1 year34.1%−12.3%
Change, 5 years−73.2%–
Beta (5Y)1.042.17
Employees73224
StockData Score
Total score56 (better)
Valuation score01 (better)
Growth score00
Performance score00
Health score55
Dividend score00
Valuation
P/S60.5× (better)84.7×
P/B4.0×1.4× (better)
FCF yield−12.5% (better)−56.2%
Fair value$1.42–
Margin of safety−138%–
Growth
Revenue growth (TTM)−51.0%–
Revenue growth, 5Y average3.8%–
Profitability
Gross margin79.5%–
Operating margin−1050% (better)−6204%
Net margin−921% (better)−5933%
FCF margin−757% (better)−4755%
Return on equity−59.1% (better)−93.6%
Financial health
Debt / equity0.000.00
Current ratio3.466.74 (better)
Altman Z-score−3.52−1.13 (better)
Piotroski F-score3 (better)2
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions82.3%91.3%
Held by insiders13.3%30.5%
Insider net buying, 12 months−$1.4M$44.7M (better)
Short interest, % of float9.1%12.3%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.